DNA 제조 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 등급별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

DNA Manufacturing Market Growth & Trends:

The global DNA manufacturing market size is projected to reach USD 14.96 billion by 2030, growing at a CAGR of 18.10% from 2025 to 2030, according to a new report by Grand View Research, Inc. The DNA manufacturing market is rapidly evolving, driven by rising demand for synthetic biology applications, personalized therapeutics, and advanced vaccine development. Increasing collaboration between biotech firms, academic institutions, and contract development and manufacturing organizations (CDMOs) is accelerating innovation and expanding market access. Technological advancements in gene synthesis, enzymatic DNA production, and automation enhance DNA manufacturing processes' scalability, speed, and precision.

This market is gaining momentum due to its critical role in various applications, including gene therapy, mRNA vaccines, diagnostic assay development, and cell engineering. As the need for high-quality plasmid DNA and GMP-grade materials grows, startups and legacy providers are expanding their capabilities to meet global demand.

Innovations in enzymatic synthesis, cell-free systems, and continuous manufacturing are reshaping traditional workflows and enabling faster turnaround times. These advancements support the broader adoption of DNA-based tools in oncology, infectious diseases, and regenerative medicine.

As the field matures, the DNA manufacturing market is positioned to be central in advancing the next generation of biotherapeutics, diagnostics, and precision health solutions.

DNA Manufacturing Market Report Highlights:

• Based on type, synthetic DNA dominated the DNA manufacturing market in 2024. This dominance is attributed to its flexibility, scalability, and expanding role in synthetic biology, genome editing, diagnostics, and next-generation therapeutics. Advances in enzymatic synthesis and automation have significantly reduced production time and costs, enabling the rapid, high-fidelity generation of custom DNA sequences. As demand grows for precision-engineered DNA across pharmaceutical, agricultural, and industrial biotech sectors, synthetic DNA continues to outpace traditional methods in innovation and adoption.
• Based on grade, R&D-grade DNA dominated the DNA manufacturing market in 2024. This dominance is primarily due to the widespread use of research-grade DNA in academic institutions, biotech startups, and early-stage drug development. Innovation in gene editing, synthetic biology, and vaccine research accelerates, and demand for cost-effective, high-quality DNA for experimental and preclinical studies continues to rise. The flexibility and faster turnaround of R&D-grade DNA make it an essential resource in iterative testing, proof-of-concept studies, and technology development.
• Based on application, cell and gene therapy dominated the DNA manufacturing market in 2024, accounting for 43.90% market share. This leadership is driven by the rapid advancement of gene-based therapeutic platforms targeting cancer, rare genetic disorders, and regenerative medicine. High demand for high-purity plasmid and synthetic DNA for use as vectors, templates, or raw material in cell and gene therapy pipelines has significantly increased production requirements.
• Based on end use, pharmaceutical and biotechnology companies dominated the DNA manufacturing market in 2024, accounting for 48.68% market share. The surge in demand for DNA-based inputs across gene therapy, vaccine production, and biologics development drives this dominance. As these companies advance clinical pipelines and bring novel therapeutics to market, their reliance on high-quality, scalable DNA manufacturing continues to grow. The increasing adoption of DNA technologies in precision medicine, oncology, and rare disease treatment further reinforces this segment's leadership.
• In May 2025, VGXI, Inc., a contract development and manufacturing organization (CDMO) specializing in nucleic acid-based therapeutics, announced the successful completion of a U.S. Food and Drug Administration (FDA) inspection at its Conroe, Texas facility. This milestone enables VGXI's client to submit a Biologics License Application (BLA) for clinical trials involving plasmid DNA, a critical component in gene therapies and mRNA vaccines. VGXI's achievement underscores its leadership in plasmid DNA manufacturing, offering scalable and high-purity production capabilities. The company has been a trusted partner in advancing life-changing medical research and innovation worldwide

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Type Segment
  • 1.2.2. Grade Segment
  • 1.2.3. Application Segment
  • 1.2.4. End Use Segment
• 1.3. Information analysis
• 1.4. Market formulation & data visualization
• 1.5. Data validation & publishing
• 1.6. Information Procurement
  • 1.6.1. Primary Research
• 1.7. Information or Data Analysis
• 1.8. Market Formulation & Validation
• 1.9. Market Model
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. DNA Manufacturing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. DNA Manufacturing Market: Type Business Analysis

• 4.1. Type Segment Dashboard
• 4.2. Global DNA Manufacturing Market Type Movement Analysis
• 4.3. Global DNA Manufacturing Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Plasmid DNA
  • 4.4.1. Global Plasmid DNA based Market, 2018 - 2030 (USD Million)
• 4.5. Synthetic DNA
  • 4.5.1. Global Synthetic DNA Market, 2018 - 2030 (USD Million)
    • 4.5.1.1. Gene Synthesis
      • 4.5.1.1.1. Global Gene Synthesis Market, 2018 - 2030 (USD Million)
    • 4.5.1.2. Oligonucleotide Synthesis
      • 4.5.1.2.1. Global Oligonucleotide Synthesis Market, 2018 - 2030 (USD Million)

Chapter 5. DNA Manufacturing Market: Grade Business Analysis

• 5.1. Grade Segment Dashboard
• 5.2. Global DNA Manufacturing Market Grade Movement Analysis
• 5.3. Global DNA Manufacturing Market Size & Trend Analysis, by Grade, 2018 to 2030 (USD Million)
• 5.4. GMP Grade
  • 5.4.1. Global GMP Grade Market, 2018 - 2030 (USD Million)
• 5.5. R&D Grade
  • 5.5.1. Global R&D Grade Market, 2018 - 2030 (USD Million)

Chapter 6. DNA Manufacturing Market: Application Business Analysis

• 6.1. Application Segment Dashboard
• 6.2. Global DNA Manufacturing Market Application Movement Analysis
• 6.3. Global DNA Manufacturing Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Cell & Gene Therapy
  • 6.4.1. Global Cell & Gene Therapy Market, 2018 - 2030 (USD Million)
• 6.5. Vaccines
  • 6.5.1. Global Vaccines Market, 2018 - 2030 (USD Million)
• 6.6. Oligonucleotide-based Drugs
  • 6.6.1. Global Oligonucleotide-based Drugs Market, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Global Others Market, 2018 - 2030 (USD Million)

Chapter 7. DNA Manufacturing Market: End Use Business Analysis

• 7.1. End Use Segment Dashboard
• 7.2. Global DNA Manufacturing Market End Use Movement Analysis
• 7.3. Global DNA Manufacturing Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Pharmaceutical and Biotechnology Companies
  • 7.4.1. Global Pharmaceutical and Biotechnology Companies Devices Market, 2018 - 2030 (USD Million)
• 7.5. Academic & Research Institutes
  • 7.5.1. Global Academic & Research Institutes Market, 2018 - 2030 (USD Million)
• 7.6. Contract Research Organizations
  • 7.6.1. Global Contract Research Organizations Market, 2018 - 2030 (USD Million)

Chapter 8. Regional DNA Manufacturing Market: Region Estimates & Trend Analysis

• 8.1. North America
  • 8.1.1. North America market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.1.2. U.S.
    • 8.1.2.1. Key country dynamics
    • 8.1.2.2. Competitive scenario
    • 8.1.2.3. Regulatory Framework
    • 8.1.2.4. Target Disease Prevalence
    • 8.1.2.5. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.1.3. Canada
    • 8.1.3.1. Key country dynamics
    • 8.1.3.2. Competitive scenario
    • 8.1.3.3. Regulatory Framework
    • 8.1.3.4. Target Disease Prevalence
    • 8.1.3.5. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.1.4. Mexico
    • 8.1.4.1. Key country dynamics
    • 8.1.4.2. Competitive scenario
    • 8.1.4.3. Regulatory Framework
    • 8.1.4.4. Target Disease Prevalence
    • 8.1.4.5. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 8.2. Europe
  • 8.2.1. Europe market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.2.2. UK
    • 8.2.2.1. Key country dynamics
    • 8.2.2.2. Competitive scenario
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Target Disease Prevalence
    • 8.2.2.5. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.2.3. Germany
    • 8.2.3.1. Key country dynamics
    • 8.2.3.2. Competitive scenario
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Target Disease Prevalence
    • 8.2.3.5. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.2.4. France
    • 8.2.4.1. Key country dynamics
    • 8.2.4.2. Competitive scenario
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Target Disease Prevalence
    • 8.2.4.5. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.2.5. Italy
    • 8.2.5.1. Key country dynamics
    • 8.2.5.2. Competitive scenario
    • 8.2.5.3. Regulatory Framework
    • 8.2.5.4. Target Disease Prevalence
    • 8.2.5.5. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.2.6. Spain
    • 8.2.6.1. Key country dynamics
    • 8.2.6.2. Competitive scenario
    • 8.2.6.3. Regulatory Framework
    • 8.2.6.4. Target Disease Prevalence
    • 8.2.6.5. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.2.7. Norway
    • 8.2.7.1. Key country dynamics
    • 8.2.7.2. Competitive scenario
    • 8.2.7.3. Regulatory Framework
    • 8.2.7.4. Target Disease Prevalence
    • 8.2.7.5. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.2.8. Sweden
    • 8.2.8.1. Key country dynamics
    • 8.2.8.2. Competitive scenario
    • 8.2.8.3. Regulatory Framework
    • 8.2.8.4. Target Disease Prevalence
    • 8.2.8.5. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.2.9. Denmark
    • 8.2.9.1. Key country dynamics
    • 8.2.9.2. Competitive scenario
    • 8.2.9.3. Regulatory Framework
    • 8.2.9.4. Target Disease Prevalence
    • 8.2.9.5. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 8.3. Asia Pacific
  • 8.3.1. Asia Pacific market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.3.2. Japan
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Competitive scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Target Disease Prevalence
    • 8.3.2.5. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.3.3. China
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Competitive scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Target Disease Prevalence
    • 8.3.3.5. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.3.4. India
    • 8.3.4.1. Key country dynamics
    • 8.3.4.2. Competitive scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Target Disease Prevalence
    • 8.3.4.5. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.3.5. Thailand
    • 8.3.5.1. Key country dynamics
    • 8.3.5.2. Competitive scenario
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Target Disease Prevalence
    • 8.3.5.5. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.3.6. South Korea
    • 8.3.6.1. Key country dynamics
    • 8.3.6.2. Competitive scenario
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Target Disease Prevalence
    • 8.3.6.5. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.3.7. Australia
    • 8.3.7.1. Key country dynamics
    • 8.3.7.2. Competitive scenario
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Target Disease Prevalence
    • 8.3.7.5. Australia market estimates and forecasts 2018 - 2030 (USD Million)
• 8.4. Latin America
  • 8.4.1. Latin America market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.4.2. Brazil
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Competitive scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Target Disease Prevalence
    • 8.4.2.5. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.4.3. Argentina
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Competitive scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Target Disease Prevalence
    • 8.4.3.5. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 8.5. Middle East & Africa
  • 8.5.1. Middle East & Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5.2. South Africa
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Competitive scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Target Disease Prevalence
    • 8.5.2.5. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5.3. Saudi Arabia
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Competitive scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Target Disease Prevalence
    • 8.5.3.5. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5.4. UAE
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Competitive scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Target Disease Prevalence
    • 8.5.4.5. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5.5. Kuwait
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Competitive scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Target Disease Prevalence
    • 8.5.5.5. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Charles River Laboratories
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Service Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. VGXI, Inc.
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Service Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Danaher (Aldevron)
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Service Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Thermo Fisher Scientific
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Service Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Lonza
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Service Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. GenScript
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Service Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Catalent
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Service Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Wuxi AppTec
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Service Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Kaneka Corp.
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Service Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Eurofins Genomics
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Service Benchmarking
    • 9.4.10.4. Strategic Initiatives